BE2016C025I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C025I2
BE2016C025I2 BE2016C025C BE2016C025C BE2016C025I2 BE 2016C025 I2 BE2016C025 I2 BE 2016C025I2 BE 2016C025 C BE2016C025 C BE 2016C025C BE 2016C025 C BE2016C025 C BE 2016C025C BE 2016C025 I2 BE2016C025 I2 BE 2016C025I2
Authority
BE
Belgium
Prior art keywords
diabetic
disease
renal
pharmaceutically acceptable
heart failure
Prior art date
Application number
BE2016C025C
Other languages
Dutch (nl)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23373410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C025(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BE2016C025I2 publication Critical patent/BE2016C025I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

The invention relates a pharmaceutical composition comprising a combination of i the AT 1- antagonist valsartan or a pharmaceutically acceptable salt thereof and ii a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, heart failure such as acute and chronic congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina whether unstable or stable, renal insufficiency diabetic and non­-diabetic, heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction such as Alzheimer's, glaucoma and stroke, comprising administering a therapeutically effective amount of the pharmaceutical composition to a mammal in need thereof.
BE2016C025C 2002-01-17 2016-05-18 BE2016C025I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34966002P 2002-01-17 2002-01-17
PCT/EP2003/000415 WO2003059345A1 (en) 2002-01-17 2003-01-16 Pharmaceutical compositions comprising valsartan and nep inhibitors

Publications (1)

Publication Number Publication Date
BE2016C025I2 true BE2016C025I2 (en) 2022-05-17

Family

ID=23373410

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C025C BE2016C025I2 (en) 2002-01-17 2016-05-18

Country Status (29)

Country Link
EP (1) EP1467728B1 (en)
JP (2) JP4820056B2 (en)
KR (2) KR100984939B1 (en)
CN (2) CN102091330B (en)
AT (1) ATE370732T1 (en)
AU (1) AU2003206738C1 (en)
BE (1) BE2016C025I2 (en)
BR (2) BRPI0306907B8 (en)
CA (1) CA2472399C (en)
CO (1) CO5600999A2 (en)
CY (2) CY1106959T1 (en)
DE (1) DE60315795T2 (en)
DK (1) DK1467728T3 (en)
EC (1) ECSP045190A (en)
ES (1) ES2290429T3 (en)
FR (1) FR16C0019I2 (en)
HU (1) HUS1600024I1 (en)
IL (2) IL162661A0 (en)
LU (1) LU93074I2 (en)
MX (1) MXPA04006917A (en)
NL (1) NL300811I2 (en)
NO (2) NO333191B1 (en)
NZ (1) NZ533968A (en)
PL (1) PL212318B1 (en)
PT (1) PT1467728E (en)
RU (1) RU2334513C3 (en)
SI (1) SI1467728T1 (en)
WO (1) WO2003059345A1 (en)
ZA (1) ZA200405117B (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512379A (en) * 2004-06-23 2008-03-11 Solvay Pharm Gmbh pharmaceutical compositions comprising nep inhibitors, endogenous endothelin production system inhibitors and at1 receptor antagonist
CA2592091A1 (en) * 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
AR057882A1 (en) * 2005-11-09 2007-12-26 Novartis Ag DOUBLE ACTION COMPOUNDS OF ANGIOTENSIN RECEPTOR BLOCKERS AND NEUTRAL ENDOPEPTIDASE INHIBITORS
WO2007106708A2 (en) * 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
CZ300801B6 (en) * 2006-06-07 2009-08-12 Helvetia Pharma A.S. Valsartan-containing composition in solid drug forms
EP2121578B1 (en) 2007-01-12 2016-08-10 Novartis AG Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
AU2008324878B2 (en) * 2007-11-06 2013-04-18 Novartis Ag Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (ARB) and neutral endopeptidase (NEP) inhibitor
CN101774941A (en) 2009-01-13 2010-07-14 浙江九洲药业股份有限公司 Method for preparing and splitting 2-acyl amino-3-biphenylyl propionic acid
PT2435409E (en) 2009-05-28 2014-11-05 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
JP5466759B2 (en) 2009-05-28 2014-04-09 ノバルティス アーゲー Substituted aminobutyric acid derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
AU2011295170B2 (en) 2010-08-23 2014-12-18 Novartis Ag Process for the preparation of intermediates for the manufacture of NEP inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
DK2887961T3 (en) * 2012-08-24 2021-07-19 Novartis Ag NEP INHIBITORS FOR THE TREATMENT OF DISEASES CHARACTERIZED IN ATRI MAGNIFICATION OR REMODELING
KR20150119107A (en) 2013-02-14 2015-10-23 노파르티스 아게 Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
EA028583B1 (en) 2013-02-14 2017-12-29 Новартис Аг Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
CN104230865B (en) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 4 amino butyric acid derivatives of biaryl substituted and its production and use
JP2016530282A (en) 2013-08-26 2016-09-29 ノバルティス アーゲー New use
DK3038654T3 (en) 2013-08-26 2020-02-03 Novartis Ag New use
CN106458857A (en) * 2014-08-27 2017-02-22 上海翰森生物医药科技有限公司 Crystalline free acid, hemicalcium salt and alfa-phenylethylamine salt of ahu-377 as well as preparation method therefor and application thereof
WO2016037098A1 (en) * 2014-09-04 2016-03-10 Concert Pharmaceuticals, Inc. Deuterated sacubitril
WO2016037552A1 (en) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 Crystalline arb-nepi compound and preparation method therefor and application thereof
CN105503760A (en) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 Crystalline ARB-NEPi dicationic compound and preparation method and application thereof
WO2016074651A1 (en) 2014-11-14 2016-05-19 Zentiva, K.S. A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377
WO2016086798A1 (en) * 2014-12-03 2016-06-09 上海翰森生物医药科技有限公司 Nep inhibitor crystalline free acid, calcium salt polymorph of same, preparation method for same, and applications thereof
HUE043014T2 (en) * 2014-12-08 2019-07-29 Crystal Pharmatech Co Ltd Crystalline forms of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
CN105693543B (en) * 2014-12-15 2018-08-10 四川海思科制药有限公司 Sha Ku is than bent analog derivative, its pharmaceutical composition, Preparation method and use
CN104826115A (en) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 Anti-heart failure pharmaceutical composition and preparation method thereof
CN106138069A (en) * 2015-04-21 2016-11-23 刘春丽 As the 1-di-sec-butyl phosphono pentane treating the uncomfortable topical agent from non-keratinization stratified epithelium tissue
JP6576469B2 (en) 2015-05-11 2019-09-18 ノバルティス アーゲー Sacvitril-valsartan dose regimen for the treatment of heart failure
WO2016193883A1 (en) 2015-05-29 2016-12-08 Novartis Ag Sacubitril and valsartan for treating metabolic disease
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106397249A (en) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 High-stability LCZ696 crystallized powder and a preparing method thereof
JP6598985B2 (en) 2015-08-28 2019-10-30 ノバルティス アーゲー New use
WO2017036420A1 (en) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 Sacubitril and valsartan-containing pharmaceutical composition and preparation method therefor
CN105348209B (en) 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 A kind of anti-heart failure medicine LCZ696 preparation method
EP3386945A1 (en) 2015-12-11 2018-10-17 Zentiva, K.S. Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
US10722471B2 (en) 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
EP3411018A1 (en) 2016-02-03 2018-12-12 Novartis AG Galenic formulations of organic compounds
EP3524250A4 (en) 2016-10-08 2020-05-20 Wuhan LL Science And Technology Development Co., Ltd. Pharmaceutical composition
WO2018211479A1 (en) 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
EP3658122B1 (en) 2017-07-28 2021-04-07 Synthon B.V. Pharmaceutical composition comprising sacubitril and valsartan
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
CN110237071B (en) * 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 Pharmaceutical preparation and use thereof
CA3110152A1 (en) 2018-08-23 2020-02-27 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
KR20210101164A (en) 2020-02-07 2021-08-18 보령제약 주식회사 Hybrid compounds and preparation method for the same
KR20200020746A (en) 2020-02-07 2020-02-26 보령제약 주식회사 Hybrid compounds and preparation method for the same
WO2021158084A1 (en) * 2020-02-07 2021-08-12 보령제약 주식회사 Hybrid compound and preparation method therefor
KR20210120560A (en) 2020-03-27 2021-10-07 주식회사 유영제약 A tablet comprising high load active ingredients and the preparation method thereof
KR20220091767A (en) 2020-12-24 2022-07-01 주식회사 보령 Pharmaceutical composition comprising sacubitril valsartan hybrid compound or pharmaceutical salts thereof as an active ingredient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1256692A (en) * 1991-02-06 1992-09-07 Schering Corporation Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
CA2168066A1 (en) * 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
CA2405496A1 (en) * 2000-04-03 2001-10-11 Richard A. Reeves Vasopeptidase inhibitors to treat isolated systolic hypertension
CA2411882C (en) * 2000-06-22 2011-09-06 Novartis Ag Solid valsartan pharmaceutical compositions
PL205715B1 (en) * 2000-07-19 2010-05-31 Novartis Ag Valsartan salts
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives

Also Published As

Publication number Publication date
RU2004125178A (en) 2005-06-10
LU93074I2 (en) 2016-07-18
MXPA04006917A (en) 2004-12-06
CY2016013I2 (en) 2016-10-05
NZ533968A (en) 2006-10-27
ECSP045190A (en) 2004-08-27
CA2472399C (en) 2012-02-21
DE60315795T2 (en) 2008-06-05
FR16C0019I2 (en) 2017-12-08
PT1467728E (en) 2007-11-14
NO333191B1 (en) 2013-03-25
NL300811I2 (en) 2016-07-27
CY2016013I1 (en) 2016-10-05
WO2003059345A1 (en) 2003-07-24
BR122018015003B8 (en) 2021-07-27
RU2334513C2 (en) 2008-09-27
NO2016009I1 (en) 2016-05-18
CY1106959T1 (en) 2012-01-25
EP1467728B1 (en) 2007-08-22
ES2290429T3 (en) 2008-02-16
PL212318B1 (en) 2012-09-28
JP2005514441A (en) 2005-05-19
HUS1600024I1 (en) 2016-06-28
ATE370732T1 (en) 2007-09-15
BR122018015003B1 (en) 2018-11-21
EP1467728A1 (en) 2004-10-20
ZA200405117B (en) 2005-08-31
DK1467728T3 (en) 2007-12-27
SI1467728T1 (en) 2008-02-29
RU2334513C3 (en) 2017-10-24
PL369773A1 (en) 2005-05-02
DE60315795D1 (en) 2007-10-04
KR20100057704A (en) 2010-05-31
BRPI0306907B1 (en) 2018-10-30
BRPI0306907B8 (en) 2021-05-25
CA2472399A1 (en) 2003-07-24
NO20043380L (en) 2004-10-07
CN102091330A (en) 2011-06-15
KR20040078127A (en) 2004-09-08
KR100984939B1 (en) 2010-10-01
FR16C0019I1 (en) 2016-06-24
CN1615134A (en) 2005-05-11
JP4820056B2 (en) 2011-11-24
CN102091330B (en) 2015-04-08
AU2003206738B2 (en) 2006-12-21
IL162661A0 (en) 2005-11-20
CO5600999A2 (en) 2006-01-31
JP2011207898A (en) 2011-10-20
AU2003206738A1 (en) 2003-07-30
NO2016009I2 (en) 2016-05-18
IL162661A (en) 2010-11-30
BR0306907A (en) 2004-12-21
AU2003206738C1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
BE2016C025I2 (en)
WO2007106708A3 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
FR16C0008I1 (en)
HK1074774A1 (en) Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
BR0317384A (en) Combinations of valsartan with cox-2 inhibitors